Literature DB >> 34073868

Mitochondrial Dynamics and Liver Cancer.

María Isabel Hernández-Alvarez1,2,3, Antonio Zorzano1,2,4.   

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer. Due to its rising incidence and limited therapeutic options, HCC has become a leading cause of cancer-related death worldwide, accounting for 85% of all deaths due to primary liver cancers. Standard therapy for advanced-stage HCC is based on anti-angiogenic drugs such as sorafenib and, more recently, lenvatinib and regorafenib as a second line of treatment. The identification of novel therapeutic strategies is urgently required. Mitochondrial dynamics describes a group of processes that includes the movement of mitochondria along the cytoskeleton, the regulation of mitochondrial morphology and distribution, and connectivity mediated by tethering and fusion/fission events. In recent years, mitochondrial dynamic processes have emerged as key processes in the maintenance of liver mitochondrial homeostasis. In addition, some data are accumulating on the role played by mitochondrial dynamics during cancer development, and specifically on how such dynamics act directly on tumor cells or indirectly on cells responsible for tumor aggression and defense. Here, we review the data that suggest mitochondrial dynamics to be involved in the development of liver tumors.

Entities:  

Keywords:  DRP1; Mitofusin 1; Mitofusin 2; NASH; OPA1; chronic liver disease; hepatocellular carcinoma; insulin resistance; liver fibrosis

Year:  2021        PMID: 34073868     DOI: 10.3390/cancers13112571

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  81 in total

1.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Mitochondrial dysfunction during in vitro hepatocyte steatosis is reversed by omega-3 fatty acid-induced up-regulation of mitofusin 2.

Authors:  Yong Zhang; Longchang Jiang; Wenjun Hu; Qichang Zheng; Wenpei Xiang
Journal:  Metabolism       Date:  2010-09-03       Impact factor: 8.694

3.  MiD49 and MiD51, new components of the mitochondrial fission machinery.

Authors:  Catherine S Palmer; Laura D Osellame; David Laine; Olga S Koutsopoulos; Ann E Frazier; Michael T Ryan
Journal:  EMBO Rep       Date:  2011-04-21       Impact factor: 8.807

4.  Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity.

Authors:  Daniel Bach; Sara Pich; Francesc X Soriano; Nathalie Vega; Bernhard Baumgartner; Josep Oriola; Jens R Daugaard; Jorge Lloberas; Marta Camps; Juleen R Zierath; Rémi Rabasa-Lhoret; Harriet Wallberg-Henriksson; Martine Laville; Manuel Palacín; Hubert Vidal; Francisca Rivera; Martin Brand; Antonio Zorzano
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

5.  Disruption of mitochondrial fission in the liver protects mice from diet-induced obesity and metabolic deterioration.

Authors:  Lixiang Wang; Takaya Ishihara; Yuta Ibayashi; Keita Tatsushima; Daiki Setoyama; Yuki Hanada; Yukina Takeichi; Shohei Sakamoto; Sadaki Yokota; Katsuyoshi Mihara; Dongchon Kang; Naotada Ishihara; Ryoichi Takayanagi; Masatoshi Nomura
Journal:  Diabetologia       Date:  2015-08-02       Impact factor: 10.122

6.  OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion.

Authors:  Christian Frezza; Sara Cipolat; Olga Martins de Brito; Massimo Micaroni; Galina V Beznoussenko; Tomasz Rudka; Davide Bartoli; Roman S Polishuck; Nika N Danial; Bart De Strooper; Luca Scorrano
Journal:  Cell       Date:  2006-07-14       Impact factor: 41.582

Review 7.  Mitochondrial dysfunction in cancer.

Authors:  Michelle L Boland; Aparajita H Chourasia; Kay F Macleod
Journal:  Front Oncol       Date:  2013-12-02       Impact factor: 6.244

8.  Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function.

Authors:  Vanessa J Davies; Andrew J Hollins; Malgorzata J Piechota; Wanfen Yip; Jennifer R Davies; Kathryn E White; Phillip P Nicols; Michael E Boulton; Marcela Votruba
Journal:  Hum Mol Genet       Date:  2007-04-11       Impact factor: 6.150

9.  MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2.

Authors:  Xiaohu Zhou; Linshi Zhang; Bichun Zheng; Yingcai Yan; Yuan Zhang; Haiyang Xie; Lin Zhou; Shusen Zheng; Weilin Wang
Journal:  Cancer Sci       Date:  2016-03-30       Impact factor: 6.716

10.  Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways.

Authors:  Qichao Huang; Lei Zhan; Haiyan Cao; Jibin Li; Yinghua Lyu; Xu Guo; Jing Zhang; Lele Ji; Tingting Ren; Jiaze An; Bingrong Liu; Yongzhan Nie; Jinliang Xing
Journal:  Autophagy       Date:  2016-04-28       Impact factor: 16.016

View more
  3 in total

1.  Negatively Regulated by miR-29c-3p, MTFR1 Promotes the Progression and Glycolysis in Lung Adenocarcinoma via the AMPK/mTOR Signalling Pathway.

Authors:  Yongmeng Li; Yanfei Liu; Kai Jin; Rui Dong; Cun Gao; Libo Si; Zitong Feng; Huiying Zhang; Hui Tian
Journal:  Front Cell Dev Biol       Date:  2021-12-01

2.  Tumor-Promoting Actions of HNRNP A1 in HCC Are Associated with Cell Cycle, Mitochondrial Dynamics, and Necroptosis.

Authors:  Biao Zhao; Xiaochen Lv; Xiaoqi Zhao; Subinuer Maimaitiaili; Yuheng Zhang; Ke Su; Hang Yu; Cheng Liu; Tong Qiao
Journal:  Int J Mol Sci       Date:  2022-09-06       Impact factor: 6.208

3.  Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma.

Authors:  Chenjun Ma; Tiantian Wei; Yingying Hua; Zhongjie Wang; Liefeng Zhang
Journal:  Int J Nanomedicine       Date:  2021-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.